1. 1129OStage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. (23rd October 2018) Authors: Leal, T A; Spira, A I; Blakely, C; He, K; Berz, D; Richards, D; Uyeki, J; Savage, A; Roque, T; Massarelli, E; Jotte, R M; Chen, I; Christensen, J; Olson, P; Tassell, V; Horn, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1509TiPRandomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR). (23rd October 2018) Authors: Elamin, Y Y; Antonoff, M; Blakely, C; Baggstorm, M; Bivona, T; Le1, X; Louie, A V; Doebele, R C; Rusthoven, C; Lee, P; Govindan, R; Swisher, S G; Papadimitrakopoulou, V A; Heymach, J V; Gomez, D R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗